Phase 4
N=66
Differences in Flare Reaction Incidence and Intensity Following Trigger Finger Injections
Trigger Finger
Bottom Line
View on ClinicalTrials.gov: NCT04900220 ↗Enrolled (actual)
66
Serious AEs
0.0%
Results posted
Jun 2023
Primary outcome: Primary: Incidence of Pain — 6; 11 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Betamethasone (Drug); Methylprednisolone (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- West Virginia University
- Primary completion
- Dec 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Incidence of Pain |
6; 11 | — |
| PRIMARY Intensity of Pain |
2.8; 2.1; 0.3; 0.8; 1.4; 2.9 | — |
| PRIMARY Incidence of Flare Reaction |
2; 5; 30; 27 | — |
Summary
Two common corticosteroids used for trigger finger treatment are betamethasone and methylprednisolone. Both injections are effective in treating trigger finger and the decision of which to use in treatment is currently a matter of the current practice and physician preference. The goal through this randomized trial is to see whether there is a difference between these two corticosteroids in inducing flare reactions and if there are any differences in the peak level of pain and their duration. Findings indicating a statistically significant difference in the incidence and/or intensity of the flare reactions would be clinically significant and would be evidence supporting the switch of current practice to one corticosteroid over the other.
Eligibility Criteria
Inclusion Criteria
- Single trigger injection
- First time for the digit
- No prior surgery on digit
Exclusion Criteria
- Current oral steroid use
- Rheumatoid arthritis
- More than one single digit involved
- Previous injection in same digit
- Prior surgery on same digit
- Other injections in the same clinic on the same day
Data sourced from ClinicalTrials.gov (NCT04900220). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.